Safety, tolerability, and pharmacokinetics of BMS-986263/ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in healthy participants: A randomised, placebo-controlled, double-blind, phase 1 study

Authors :: B. Soule
Giridhar S. Tirucherai
Rose C. Christian
U. Kavita
S. Kundu
Source :: Journal of Hepatology. 68:S112
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
Double blind
03 medical and health sciences
030104 developmental biology
Hepatology
Pharmacokinetics
business.industry
Medicine
Safety tolerability
Pharmacology
Placebo
business

Full Text Access

Tools